Registration Dossier

Toxicological information

Acute Toxicity: other routes

Currently viewing:

Administrative data

Endpoint:
acute toxicity: other routes
Type of information:
migrated information: read-across based on grouping of substances (category approach)
Adequacy of study:
supporting study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Review of non-standard literature studies

Data source

Reference
Reference Type:
other: Criteria Document
Title:
Criteria Document for Hexavalent Chromium
Author:
Cross HJ et al
Year:
1997
Bibliographic source:
Institute of Occupational Health, UK

Materials and methods

Principles of method if other than guideline:
Reviews of various published, non-standard mechanistic studies.
GLP compliance:
no
Remarks:
Published studies
Limit test:
no

Test material

Reference
Name:
Unnamed
Type:
Constituent
Details on test material:
The IOH review summarises the results of a number of studies performed with potassium dichromate, potassium chromate or sodium chromate following subcutaneous injection or intraperitoneal administration at dose levels of 2 mg Cr (VI) / kg.

Test animals

Species:
rat
Sex:
not specified

Administration / exposure

Route of administration:
other: Intraperitoneal or subcutaneous
Doses:
2 mg/kg bw Cr (VI)
No. of animals per sex per dose:
Not reported

Results and discussion

Any other information on results incl. tables

Effects indicative of renal toxicity (altered urinary protein or enzyme levels, histopathology of the proximal tubular epithelium) were reported in these studies.

Applicant's summary and conclusion

Conclusions:
The acute administration of low doses of Cr (VI) compounds by parenteral (subcutaneous or intraperitoneal) injection to rats was found to cause kidney toxicity.
Executive summary:

Acute administration of low doses of Cr (VI) compounds by parenteral (subcutaneous or intraperitoneal) injection to rats was found to cause kidney toxicity. These findings are therefore consistent with the known effects of Cr (VI) toxicity and do not raise any additional concerns. The relatively low dose levels resulting in toxicity in these studies compared to those seen following oral and dermal dosing reflects the relatively poor bioavailability of Cr (VI) compounds by these routes of exposure.